Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
8.25
-0.18 (-2.14%)
At close: Jul 29, 2026, 4:00 PM EDT
8.25
0.00 (0.00%)
After-hours: Jul 29, 2026, 4:04 PM EDT
Akari Therapeutics, Earnings Call Transcripts
Fiscal Year 2026
-
The ADC platform has expanded with AKTX-102, demonstrating scalability and innovation in targeting challenging antigens like CEACAM5. Key milestones include an IND/CTA filing for AKTX-101 by year-end and initial clinical data within 18 months.
Fiscal Year 2025
-
A novel immuno-oncology ADC platform is advancing with a unique PH1 payload that targets the spliceosome, activating immune responses and showing robust preclinical efficacy, especially in combination with checkpoint inhibitors. The company is pivoting to oncology, leveraging strong leadership and seeking partnerships to expand its differentiated platform.